NCT04113538View on ClinicalTrials.gov

Treat and Extend Analysis Trial With Aflibercept in Wet-AMD

PHASE3UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 24, 2019

Primary Completion Date

January 31, 2023

Study Completion Date

May 31, 2023

Conditions
Wet Age-related Macular Degeneration
Interventions
DRUG

Aflibercept

Intraocular injection of 2 ml (40mg/ml)

Trial Locations (1)

J1G 2V4

GOGIUNTA, Sherbrooke

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Michel Giunta

OTHER

NCT04113538 - Treat and Extend Analysis Trial With Aflibercept in Wet-AMD | Biotech Hunter | Biotech Hunter